STERIS (NYSE:STE) Director Sells $310,284.31 in Stock

STERIS plc (NYSE:STE) Director Richard Breeden sold 1,481 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total transaction of $310,284.31. Following the completion of the sale, the director owned 38,964 shares in the company, valued at $8,163,347.64. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

STERIS Stock Down 0.1%

NYSE STE opened at $212.13 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The company’s 50 day simple moving average is $217.24 and its 200 day simple moving average is $239.09. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44. The company has a market capitalization of $20.70 billion, a P/E ratio of 26.75 and a beta of 0.93.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the firm earned $2.74 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts expect that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Piper Sandler restated an “overweight” rating and set a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Institutional Investors Weigh In On STERIS

A number of large investors have recently made changes to their positions in STE. Norges Bank acquired a new stake in shares of STERIS during the fourth quarter valued at approximately $320,298,000. AQR Capital Management LLC increased its stake in STERIS by 178.6% in the 3rd quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock valued at $291,704,000 after buying an additional 758,423 shares during the period. Boston Partners acquired a new position in STERIS in the 3rd quarter valued at approximately $158,982,000. Orbis Allan Gray Ltd increased its stake in STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after buying an additional 556,088 shares during the period. Finally, Janus Henderson Group PLC increased its stake in STERIS by 25.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock valued at $411,995,000 after buying an additional 380,504 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.